Quoin Pharmaceuticals (QNRX) Proxy Filing summary

Executive summary

• The annual general meeting is scheduled for August 21, 2025, with a record date of July 16, 2025, for voting eligibility.

• Shareholders will vote on seven key proposals, including director elections, share capital increase, compensation policies, equity plans, director compensation, option grants, and auditor appointment.

• The board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Proposals include re-election of seven directors, increasing authorized share capital to 5 billion shares, adopting a new compensation policy, approving a 2025 equity incentive plan, changes to non-employee director compensation, specific option grants, and appointing CBIZ CPAs P.C. as auditor.

• Shareholders holding at least 1% of voting rights may submit proposals for future meetings.

Board of directors and corporate governance

• The board consists of seven members, with five deemed independent under Nasdaq rules.

• Three standing committees: Audit, Compensation, and Nominating and Governance, each meeting regularly.

• Directors are expected to attend annual meetings; committee charters are available online.

• The board oversees risk management, compliance, and shareholder communications.